Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats

作者：Hui Ma, Jing Kong, Yulin Wang, Junlong Li, Nai-Hao Hei, Xinran Cao, Jingjing Yang, Wenjiang Yan, Wenjing Liang, Hong-Yan Dai, Bo Dong · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.15595 · 被引用次数：32 · 研究领域：Chemotherapy-induced cardiotoxicity and mitigation、Coenzyme Q10 studies and effects、Apelin-related biomedical research

// Hui Ma 1, 2 , Jing Kong 3 , Yu-Lin Wang 1, 2 , Jun-Long Li 1, 2 , Nai-Hao Hei 1, 2 , Xin-Ran Cao 1, 2 , Jing-Jing Yang 3 , Wen-Jiang Yan 3 , Wen-Jing Liang 3 , Hong-Yan Dai 4 , Bo Dong 1, 2 1 Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China 2 Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China 3 Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, China 4 Cardiovascular department, Qingdao Municipal Hospital, Qingdao, China Correspondence to: Bo Dong, email: dongbo1@medmail.com.cn Keywords: angiotensin-converting enzyme 2, cilazapril, doxorubicin-induced cardiomyopathy, gene therapy Received: November 18, 2016      Accepted: February 13, 2017      Published: February 21, 2017 ABSTRACT Angiotensin-converting enzyme 2 (ACE2) is considered a potential therapeutic target of the renin-angiotensin system (RAS) for the treatment of cardiovascular diseases. We aimed to explore the effects of ACE2 overexpression on doxorubicin-induced cardiomyopathy in rats. Rats were randomly divided into treatment and control groups. The rats of treatment group were injected intraperitoneally with 6 doses of doxorubicin (2.5 mg/kg) within a period of two weeks. Two weeks after the initial injection of doxorubicin, these rats were randomly divided into Mock, Ad-EGFP, Ad-ACE2, and Cilazapri...